

Roderick Skinner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2951537/publications.pdf>

Version: 2024-02-01

143
papers

6,310
citations

66343

42
h-index

79698

73
g-index

144
all docs

144
docs citations

144
times ranked

6312
citing authors

#	ARTICLE	IF	CITATIONS
1	Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>Lancet Oncology, The</i> , 2015, 16, e123-e136.	10.7	453
2	Long-term Cause-Specific Mortality Among Survivors of Childhood Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 172.	7.4	375
3	A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: A report from the international late effects of Childhood Cancer Guideline Harmonization Group. <i>Pediatric Blood and Cancer</i> , 2013, 60, 543-549.	1.5	275
4	Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. <i>Lancet Oncology, The</i> , 2016, 17, e231-e239.	10.7	194
5	Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration With the PanCareSurFup Consortium. <i>Journal of Clinical Oncology</i> , 2016, 34, 3440-3450.	1.6	173
6	Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>Lancet Oncology, The</i> , 2013, 14, e621-e629.	10.7	162
7	Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. <i>Lancet Oncology, The</i> , 2017, 18, e75-e90.	10.7	158
8	Long-term follow-up of people who have survived cancer during childhood. <i>Lancet Oncology, The</i> , 2006, 7, 489-498.	10.7	148
9	True. <i>British Journal of Cancer</i> , 2000, 82, 1636-1645.	6.4	146
10	Similar outcome of upfront unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT. <i>British Journal of Haematology</i> , 2015, 171, 585-594.	2.5	146
11	Surveillance for Late Effects in Childhood Cancer Survivors. <i>Journal of Clinical Oncology</i> , 2018, 36, 2216-2222.	1.6	134
12	Chronic ifosfamide nephrotoxicity in children. <i>Medical and Pediatric Oncology</i> , 2003, 41, 190-197.	1.0	127
13	T-cell receptor α and CD19+ cell-depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1417-1426.e1.	2.9	119
14	Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experience. <i>British Journal of Haematology</i> , 2012, 157, 339-346.	2.5	105
15	Single amino acid charge switch defines clinically distinct proline-serine-threonine phosphatase-interacting protein 1 (PSTPIP1)-associated inflammatory diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1337-1345.	2.9	103
16	Risk factors for ifosfamide nephrotoxicity in children. <i>Lancet, The</i> , 1996, 348, 578-580.	13.7	102
17	Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factors. <i>European Journal of Cancer</i> , 2009, 45, 3213-3219.	2.8	101
18	Survivorship after childhood cancer: PanCare: A European Network to promote optimal long-term care. <i>European Journal of Cancer</i> , 2015, 51, 1203-1211.	2.8	98

#	ARTICLE	IF	CITATIONS
19	Childhood cancer survivor cohorts in Europe. <i>Acta Oncologica</i> , 2015, 54, 655-668.	1.8	97
20	Long term cause specific mortality among 34%489 five year survivors of childhood cancer in Great Britain: population based cohort study. <i>BMJ, The</i> , 2016, 354, i4351.	6.0	95
21	Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>Lancet Oncology, The</i> , 2021, 22, e57-e67.	10.7	95
22	Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. <i>Lancet Oncology, The</i> , 2019, 20, e29-e41.	10.7	90
23	National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: The Need for Pediatric-Specific Long-Term Follow-up Guidelines. <i>Biology of Blood and Marrow Transplantation</i> . 2012. 18. 334-347.	2.0	82
24	Long-term follow-up of children treated for cancer: why is it necessary, by whom, where and how?. <i>Archives of Disease in Childhood</i> , 2007, 92, 257-260.	1.9	75
25	Health-related quality of life in survivors of BMT for paediatric malignancy: a systematic review of the literature. <i>Bone Marrow Transplantation</i> , 2008, 42, 73-82.	2.4	70
26	The "Survivorship Passport"™ for childhood cancer survivors. <i>European Journal of Cancer</i> , 2018, 102, 69-81.	2.8	67
27	Young adult survivors of childhood acute lymphoblastic leukemia show evidence of chronic inflammation and cellular aging. <i>Cancer</i> , 2017, 123, 4207-4214.	4.1	66
28	Models of Care for Survivors of Childhood Cancer From Across the Globe: Advancing Survivorship Care in the Next Decade. <i>Journal of Clinical Oncology</i> , 2018, 36, 2223-2230.	1.6	65
29	Assessment of chemotherapy-associated nephrotoxicity in children with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 81-92.	2.3	62
30	Evidence-based recommendations for the organization of long-term follow-up care for childhood and adolescent cancer survivors: a report from the PanCareSurFup Guidelines Working Group. <i>Journal of Cancer Survivorship</i> , 2019, 13, 759-772.	2.9	60
31	Variation in policies for the management of febrile neutropenia in United Kingdom Children's Cancer Study Group centres. <i>Archives of Disease in Childhood</i> , 2007, 92, 495-498.	1.9	57
32	Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, Adolescent, and Young Adult Cancer From the International Guideline Harmonization Group. <i>Journal of Clinical Oncology</i> , 2020, 38, 4194-4207.	1.6	55
33	Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance. <i>Pediatric Nephrology</i> , 2018, 33, 215-225.	1.7	53
34	Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. <i>Lancet Haematology,the</i> , 2020, 7, e50-e60.	4.6	53
35	Nephrotoxicity" What Do We Know and What Don't We Know?. <i>Journal of Pediatric Hematology/Oncology</i> , 2011, 33, 128-134.	0.6	51
36	Pregnancy and Labor Complications in Female Survivors of Childhood Cancer: The British Childhood Cancer Survivor Study. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	51

#	ARTICLE	IF	CITATIONS
37	Best practice in assessing ototoxicity in children with cancer. <i>European Journal of Cancer</i> , 2004, 40, 2352-2354.	2.8	50
38	Nephrotoxicity in survivors of Wilms' tumours in the North of England. <i>British Journal of Cancer</i> , 2002, 87, 1092-1098.	6.4	49
39	Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose. <i>Pediatric Blood and Cancer</i> , 2010, 54, 983-989.	1.5	49
40	Improving Male Reproductive Health After Childhood, Adolescent, and Young Adult Cancer: Progress and Future Directions for Survivorship Research. <i>Journal of Clinical Oncology</i> , 2018, 36, 2160-2168.	1.6	48
41	Recommendations for the surveillance of cancer-related fatigue in childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>Journal of Cancer Survivorship</i> , 2020, 14, 923-938.	2.9	48
42	Follow-Up Programs for Childhood Cancer Survivors in Europe: A Questionnaire Survey. <i>PLoS ONE</i> , 2012, 7, e53201.	2.5	47
43	European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies. <i>Pediatric Blood and Cancer</i> , 2016, 63, 139-148.	1.5	45
44	Transition guidelines: An important step in the future care for childhood cancer survivors. A comprehensive definition as groundwork. <i>European Journal of Cancer</i> , 2016, 54, 64-68.	2.8	44
45	Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1422-1428.	2.0	43
46	BCSH/BSBMT/UK clinical virology network guideline: diagnosis and management of common respiratory viral infections in patients undergoing treatment for haematological malignancies or stem cell transplantation. <i>British Journal of Haematology</i> , 2016, 173, 380-393.	2.5	40
47	Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia. <i>Annals of Hematology</i> , 2015, 94, 297-306.	1.8	38
48	The role of the RAS pathway in iAMP21-ALL. <i>Leukemia</i> , 2016, 30, 1824-1831.	7.2	38
49	Risk of Subsequent Bone Cancers Among 69 460 Five-Year Survivors of Childhood and Adolescent Cancer in Europe. <i>Journal of the National Cancer Institute</i> , 2018, 110, 183-194.	6.3	38
50	European PanCareFollowUp Recommendations for surveillance of late effects of childhood, adolescent, and young adult cancer. <i>European Journal of Cancer</i> , 2021, 154, 316-328.	2.8	38
51	Health-related quality of life and financial impact of caring for a child with Thalassaemia Major in the UK. <i>Child: Care, Health and Development</i> , 2010, 36, 118-122.	1.7	37
52	Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>Lancet Oncology</i> , 2021, 22, e68-e80.	10.7	37
53	Risk of Soft-Tissue Sarcoma Among 69 460 Five-Year Survivors of Childhood Cancer in Europe. <i>Journal of the National Cancer Institute</i> , 2018, 110, 649-660.	6.3	36
54	Counseling and surveillance of obstetrical risks for female childhood, adolescent, and young adult cancer survivors: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 3-15.	1.3	35

#	ARTICLE	IF	CITATIONS
55	The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late Effects of Children Undergoing Hematopoietic Cell Transplantation for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 24-33.	2.0	33
56	The views of European clinicians on guidelines for long-term follow-up of childhood cancer survivors. <i>Pediatric Blood and Cancer</i> , 2015, 62, 322-328.	1.5	32
57	Strategies to prevent nephrotoxicity of anticancer drugs. <i>Current Opinion in Oncology</i> , 1995, 7, 310-315.	2.4	30
58	The PanCareSurFup consortium: research and guidelines to improve lives for survivors of childhood cancer. <i>European Journal of Cancer</i> , 2018, 103, 238-248.	2.8	30
59	The long-term psychosocial impact of cancer: the views of young adult survivors of childhood cancer. <i>European Journal of Cancer Care</i> , 2016, 25, 428-439.	1.5	29
60	Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 622-637.	11.4	29
61	Recommendations for the surveillance of education and employment outcomes in survivors of childhood, adolescent, and young adult cancer: A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>Cancer</i> , 2022, 128, 2405-2419.	4.1	29
62	Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters. <i>Bone Marrow Transplantation</i> , 2016, 51, 1482-1489.	2.4	28
63	Renal and Pulmonary Late Effects of Cancer Therapy. <i>Seminars in Oncology</i> , 2013, 40, 757-773.	2.2	27
64	Recent advances in the management of graft-versus-host disease. <i>Archives of Disease in Childhood</i> , 2014, 99, 1150-1157.	1.9	27
65	Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1093-1096.	2.3	26
66	Coronary artery disease surveillance among childhood, adolescent and young adult cancer survivors: A systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>European Journal of Cancer</i> , 2021, 156, 127-137.	2.8	26
67	Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia. <i>Blood</i> , 2022, 140, 1875-1890.	1.4	26
68	Guidance regarding COVID-19 for survivors of childhood, adolescent, and young adult cancer: A statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28702.	1.5	25
69	Recommendations for the surveillance of mental health problems in childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>Lancet Oncology</i> , 2022, 23, e184-e196.	10.7	25
70	Clinical outcomes and health-related quality of life (HRQOL) following haemopoietic stem cell transplantation (HSCT) for paediatric leukaemia. <i>Child: Care, Health and Development</i> , 2011, 37, 571-580.	1.7	24
71	New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT. <i>Blood Advances</i> , 2020, 4, 2418-2429.	5.2	24
72	Surveillance for subsequent neoplasms of the CNS for childhood, adolescent, and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>Lancet Oncology</i> , 2021, 22, e196-e206.	10.7	24

#	ARTICLE	IF	CITATIONS
73	Epidemiology of leukaemia and lymphoma in children and young adults from the north of England, 1990-2002. <i>European Journal of Cancer</i> , 2009, 45, 420-427.	2.8	23
74	Plasma coenzyme Q10 in children and adolescents undergoing doxorubicin therapy. <i>Clinica Chimica Acta</i> , 2000, 302, 1-9.	1.1	22
75	Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: effectiveness and a scoring system for initiating treatment. <i>Bone Marrow Transplantation</i> , 2003, 31, 591-597.	2.4	21
76	Prevention and management of central venous catheter occlusion and thrombosis in children with cancer. <i>Pediatric Blood and Cancer</i> , 2008, 50, 826-830.	1.5	21
77	Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients (NICE Clinical) Tj ETQq1 1 0.784314 rgBT /Qw	0.5	21
78	Long-term survivors of childhood cancer: cure and care- the Erice Statement (2006) revised after 10 years (2016). <i>Journal of Cancer Survivorship</i> , 2018, 12, 647-650.	2.9	21
79	T-CELL FREQUENCY ANALYSIS DOES NOT PREDICT THE INCIDENCE OF GRAFT-VERSUS-HOST DISEASE IN HLA-MATCHED SIBLING BONE MARROW TRANSPLANTATION. <i>Transplantation</i> , 2000, 70, 488-493.	1.0	20
80	Hypothalamic-Pituitary and Other Endocrine Surveillance Among Childhood Cancer Survivors. <i>Endocrine Reviews</i> , 2022, 43, 794-823.	20.1	20
81	PEPtalk: postexposure prophylaxis against varicella in children with cancer. <i>Archives of Disease in Childhood</i> , 2011, 96, 841-845.	1.9	18
82	HSCT is effective in patients with PSTPIP1-associated myeloid-related proteinemia inflammatory (PAMI) syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 250-255.e1.	2.9	18
83	The European multistakeholder PanCareFollowUp project: novel, person-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for cancer survivors and caregivers. <i>European Journal of Cancer</i> , 2021, 153, 74-85.	2.8	18
84	The PanCareFollowUp Care Intervention: A European harmonised approach to person-centred guideline-based survivorship care after childhood, adolescent and young adult cancer. <i>European Journal of Cancer</i> , 2022, 162, 34-44.	2.8	17
85	Molecular diagnosis of vascular access device-associated infection in children being treated for cancer or leukaemia. <i>Clinical Microbiology and Infection</i> , 2008, 14, 213-220.	6.0	16
86	Developing a national "low risk" febrile neutropenia framework for use in children and young people's cancer care. <i>Supportive Care in Cancer</i> , 2013, 21, 1241-1251.	2.2	16
87	Routine vaccination practice after adult and paediatric allogeneic haematopoietic stem cell transplant: a survey of UK NHS programmes. <i>Bone Marrow Transplantation</i> , 2017, 52, 775-777.	2.4	16
88	Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group. <i>Cancer Treatment Reviews</i> , 2021, 100, 102296.	7.7	16
89	Novel mutations in a child with congenital amegakaryocytic thrombocytopenia. <i>British Journal of Haematology</i> , 2006, 135, 742-743.	2.5	15
90	A reaudit of current febrile neutropenia practice in UK paediatric oncology centres prior to implementation of NICE guidance. <i>Archives of Disease in Childhood</i> , 2013, 98, 315-316.	1.9	15

#	ARTICLE	IF	CITATIONS
91	Risk of cerebrovascular disease among 13â€‰%457 fiveâ€‰year survivors of childhood cancer: A populationâ€‰based cohort study. <i>International Journal of Cancer</i> , 2021, 148, 572-583.	5.1	15
92	â€˜Acceptabilityâ€™ of a new oral suspension formulation of mercaptopurine in children with acute lymphoblastic leukaemia. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 387-395.	0.9	14
93	Nephrotoxicity of cancer treatment in children. <i>Pediatric Health</i> , 2010, 4, 519-538.	0.3	12
94	Risk of subsequent primary leukaemias among 69,460 five-year survivors of childhood cancer diagnosed from 1940 to 2008 in Europe: A cohort study within PanCareSurFup. <i>European Journal of Cancer</i> , 2019, 117, 71-83.	2.8	12
95	Developing international consensus for late effects screening and guidance. <i>Current Opinion in Supportive and Palliative Care</i> , 2013, 7, 303-308.	1.3	11
96	Secondary Malignant Neoplasms Following Haematopoietic Stem Cell Transplantation in Childhood. <i>Children</i> , 2015, 2, 146-173.	1.5	11
97	A School Passport as Part of a Protocol to Assist Educational Reintegration After Medulloblastoma Treatment in Childhood. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1636-1642.	1.5	11
98	PEPtalk2: results of a pilot randomised controlled trial to compare VZIG and aciclovir as postexposure prophylaxis (PEP) against chickenpox in children with cancer. <i>Archives of Disease in Childhood</i> , 2019, 104, 25-29.	1.9	11
99	Increased risk of cardiac ischaemia in a pan-European cohort of 36 205 childhood cancer survivors: a PanCareSurFup study. <i>Heart</i> , 2021, 107, 33-41.	2.9	11
100	Impact of era of diagnosis on causeâ€‰specific late mortality among 77â€‰%423 fiveâ€‰year European survivors of childhood and adolescent cancer: The <sc>PanCareSurFup</sc> consortium. <i>International Journal of Cancer</i> , 2022, 150, 406-419.	5.1	11
101	Late Cardiac Events after Childhood Cancer: Methodological Aspects of the Pan-European Study PanCareSurFup. <i>PLoS ONE</i> , 2016, 11, e0162778.	2.5	11
102	Acute changes in urine protein excretion may predict chronic ifosfamide nephrotoxicity: a preliminary observation. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 41, 413-416.	2.3	10
103	The development of health behaviour change interventions for childhood cancer survivors: The need for a behavioural science approach. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28500.	1.5	10
104	Excellent overall and chronic graftâ€‰versusâ€‰hostâ€‰diseaseâ€‰free eventâ€‰free survival in Fanconi anaemia patients undergoing matched relatedâ€‰and unrelatedâ€‰donor bone marrow transplantation using alemtuzumabâ€‰“Fluâ€‰Cy: the UK experience. <i>British Journal of Haematology</i> , 2021, 193, 804-813.	2.5	10
105	Preventing platinum-induced ototoxicity in children-is there a potential role for sodium thiosulfate?. <i>Pediatric Blood and Cancer</i> , 2006, 47, 120-122.	1.5	9
106	Treating childhood acute lymphoblastic leukemia in Malawi. <i>Haematologica</i> , 2013, 98, e1-e3.	3.5	9
107	The Concept of Cancer Survivorship and Models for Long-Term Follow-Up. <i>Frontiers of Hormone Research</i> , 2021, 54, 1-15.	1.0	9
108	Childhood cancer survivorship care during the COVID-19 pandemic: an international report of practice implications and provider concerns. <i>Journal of Cancer Survivorship</i> , 2022, 16, 1390-1400.	2.9	9

#	ARTICLE	IF	CITATIONS
109	Childhood cancer survivorsâ€™ perceptions of the barriers and facilitators to physical activity: a systematic review and thematic synthesis of qualitative evidence using the Theoretical Domains Framework. <i>Health Psychology Review</i> , 2022, , 1-36.	8.6	9
110	Variations in screening and management practices for subsequent asymptomatic meningiomas in childhood, adolescent and young adult cancer survivors. <i>Journal of Neuro-Oncology</i> , 2020, 147, 417-425.	2.9	8
111	Identifying and exploring the self-management strategies used by childhood cancer survivors. <i>Journal of Cancer Survivorship</i> , 2021, 15, 344-357.	2.9	8
112	Accuracy of cystatin C for the detection of abnormal renal function in children undergoing chemotherapy for malignancy: a systematic review using individual patient data. <i>Supportive Care in Cancer</i> , 2017, 26, 1635-1644.	2.2	7
113	Non-posttransplant lymphoproliferative disorder malignancy after hematopoietic stem cell transplantation in patients with primary immunodeficiency: UK experience. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 2319-2321.e1.	2.9	7
114	Should paediatric central lines be aspirated before use?. <i>Archives of Disease in Childhood</i> , 2007, 92, 517-518.	1.9	6
115	Donor lymphocyte infusions for post-transplant relapse of refractory anemia with excess blasts and monosomy 7. <i>Pediatric Blood and Cancer</i> , 2008, 50, 670-672.	1.5	6
116	Long-term effects of cancer therapy in children â€“ functional effects, late mortality and long-term follow-up. <i>Paediatrics and Child Health (United Kingdom)</i> , 2012, 22, 248-252.	0.4	6
117	Health problems in survivors of childhood cancer: the need for international collaboration in long-term follow-up care. <i>Future Oncology</i> , 2013, 9, 1667-1670.	2.4	6
118	High transplant-related mortality associated with haematopoietic stem cell transplantation for paediatric therapy-related acute myeloid leukaemia (t-AML). A study on behalf of the United Kingdom Paediatric Blood and Bone Marrow Transplant Group. <i>Bone Marrow Transplantation</i> , 2018, 53, 1165-1169.	2.4	6
119	Male breast cancer after childhood cancer: Systematic review and analyses in the PanCareSurFup cohort. <i>European Journal of Cancer</i> , 2022, 165, 27-47.	2.8	6
120	INVASIVE ASPERGILLOSIS OF THE SMALL BOWEL IN AN INFANT WITH ACUTE MYELOID LEUKEMIA AND INTESTINAL OBSTRUCTION. <i>Pediatric Hematology and Oncology</i> , 2009, 26, 84-91.	0.8	5
121	Long-term effects of cancer therapy in children â€“ organs, systems and tissues. <i>Paediatrics and Child Health (United Kingdom)</i> , 2012, 22, 201-206.	0.4	5
122	Views of Childhood Cancer Survivors and Their Families on the Provision and Format of a Treatment Summary. <i>Journal of Pediatric Hematology/Oncology</i> , 2013, 35, 193-196.	0.6	5
123	An Association of Cancer Physiciansâ€™ strategy for improving services and outcomes for cancer patients. <i>Ecancermedalscience</i> , 2016, 10, 608.	1.1	5
124	Risk of digestive cancers in a cohort of 69 460 five-year survivors of childhood cancer in Europe: the PanCareSurFup study. <i>Gut</i> , 2020, , gutjnl-2020-322237.	12.1	5
125	The Critical Role of Clinical Practice Guidelines and Indicators in High-Quality Survivorship After Childhood Cancer. <i>Pediatric Clinics of North America</i> , 2020, 67, 1069-1081.	1.8	5
126	Renal and Hepatic Health After Childhood Cancer. <i>Pediatric Clinics of North America</i> , 2020, 67, 1203-1217.	1.8	5

#	ARTICLE	IF	CITATIONS
127	Varicella postexposure prophylaxis in children with cancer: urgent need for a randomised controlled trial. <i>Archives of Disease in Childhood</i> , 2012, 97, 853.2-854.	1.9	4
128	Evaluation of Infection Control Advice for Patients at Risk of Chemotherapy-Induced Neutropenia in 2 Pediatric Oncology Centers: Cape Town, South Africa, and Newcastle-Upon-Tyne, UK. <i>Pediatric Hematology and Oncology</i> , 2012, 29, 73-84.	0.8	4
129	Central nervous system lesions in Malawian children: identifying the treatable. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2012, 106, 567-569.	1.8	4
130	The European Experience of Establishing Guidelines for Surveillance of the Childhood Cancer Survivor. , 2015, , 25-35.		4
131	Health promotion and information provision during long-term follow-up for childhood cancer survivors: A service evaluation. <i>Pediatric Hematology and Oncology</i> , 2016, 33, 359-370.	0.8	4
132	Accelerated Aging in Bone Marrow Transplant Survivors. <i>JAMA Oncology</i> , 2016, 2, 1267-1268.	7.1	4
133	Haploidentical CD3 TCR $\alpha\beta$ and CD19-depleted second stem cell transplant for steroid-resistant acute skin graft versus host disease. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 603-605.e1.	2.9	4
134	Large variation in assessment and outcome definitions to describe the burden of long-term morbidity in childhood cancer survivors: A systematic review. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28611.	1.5	4
135	Inconsistencies in fertility preservation for young people with cancer in the UK. <i>Archives of Disease in Childhood</i> , 2022, 107, 265-270.	1.9	4
136	Editorial: Adverse and Toxic Effects of Childhood Cancer Treatments. <i>Frontiers in Oncology</i> , 2021, 11, 795664.	2.8	4
137	Vascular access for daunorubicin during childhood acute lymphoblastic leukaemia induction treatment: A UKCCSG supportive care group and MRC childhood leukaemia working party survey. <i>European Journal of Oncology Nursing</i> , 2008, 12, 476-478.	2.1	3
138	Influenza vaccination during cancer therapy. <i>Archives of Disease in Childhood</i> , 2010, 95, 569-570.	1.9	3
139	Social inequalities in treatment receipt for childhood cancers in Ireland: A population-based analysis. <i>International Journal of Cancer</i> , 2022, 150, 941-951.	5.1	3
140	Reply: Methotrexate neurotoxicity due to drug interactions: an inadequate folinic acid effect. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 841-842.	2.3	2
141	Optimizing Detection of Low Bone Mineral Density in Childhood Cancer Survivors. <i>Journal of Clinical Oncology</i> , 2019, 37, 2193-2195.	1.6	2
142	Prevention of varicella in children with cancer: Is it time to reconsider our strategy?. <i>Pediatric Blood and Cancer</i> , 2008, 51, 451-452.	1.5	0
143	Challenges in the Management of Paediatric Febrile Neutropenia. <i>Current Pediatric Reviews</i> , 2009, 5, 229-233.	0.8	0